MLM Share Price

Open 0.43 Change Price %
High 0.43 1 Day 0.01 2.38
Low 0.42 1 Week 0.01 2.38
Close 0.43 1 Month -0.01 -2.27
Volume 937803 1 Year 0.10 30.30
52 Week High 0.64
52 Week Low 0.29
MLM Important Levels
Resistance 2 0.44
Resistance 1 0.44
Pivot 0.43
Support 1 0.42
Support 2 0.42
BIT Italy Most Active Stocks
SPM 0.42 -6.67%
SPM 0.42 -6.67%
ISP 2.08 -1.89%
TIT 0.76 -1.30%
PMI 0.36 0.00%
PMI 0.36 0.00%
ENEL 4.00 0.76%
UCG 12.16 -2.25%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
EEMS 0.14 16.67%
TAS 4.15 14.96%
TAS 4.15 14.96%
TAS 4.15 14.96%
POPR 0.32 6.67%
VRW 1.13 6.60%
More..
BIT Italy Top Losers Stocks
PRS 0.09 -10.00%
PRS 0.09 -10.00%
PRS 0.09 -10.00%
PRS 0.09 -10.00%
SPMR 5.41 -9.83%
STEF 0.12 -7.69%
SPM 0.42 -6.67%
SPM 0.42 -6.67%
MEC 0.16 -5.88%
MEC 0.16 -5.88%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 1.5
As on 24th Feb 2017 MLM Share Price closed @ 0.43 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.39 & Sell for SHORT-TERM with Stoploss of 0.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for February
1st Target up-side 0.45
2nd Target up-side 0.47
3rd Target up-side 0.5
1st Target down-side 0.37
2nd Target down-side 0.35
3rd Target down-side 0.32
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.